These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 18936427)

  • 1. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis.
    Krumbholz M; Meinl I; Kümpfel T; Hohlfeld R; Meinl E
    Neurology; 2008 Oct; 71(17):1350-4. PubMed ID: 18936427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune surveillance in multiple sclerosis patients treated with natalizumab.
    Stüve O; Marra CM; Jerome KR; Cook L; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Hemmer B; Monson NL; Racke MK
    Ann Neurol; 2006 May; 59(5):743-7. PubMed ID: 16634029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotoxicity profile of natalizumab.
    Wehner NG; Gasper C; Shopp G; Nelson J; Draper K; Parker S; Clarke J
    J Immunotoxicol; 2009 Jun; 6(2):115-29. PubMed ID: 19589098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
    Stüve O; Marra CM; Bar-Or A; Niino M; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Jerome KR; Cook L; Grand'Maison F; Hemmer B; Monson NL; Racke MK
    Arch Neurol; 2006 Oct; 63(10):1383-7. PubMed ID: 17030653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells.
    Putzki N; Baranwal MK; Tettenborn B; Limmroth V; Kreuzfelder E
    Eur Neurol; 2010; 63(5):311-7. PubMed ID: 20453514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natalizumab effects on immune cell responses in multiple sclerosis.
    Niino M; Bodner C; Simard ML; Alatab S; Gano D; Kim HJ; Trigueiro M; Racicot D; Guérette C; Antel JP; Fournier A; Grand'Maison F; Bar-Or A
    Ann Neurol; 2006 May; 59(5):748-54. PubMed ID: 16634035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.
    Wipfler P; Oppermann K; Pilz G; Afazel S; Haschke-Becher E; Harrer A; Huemer M; Kunz A; Golaszewski S; Staffen W; Ladurner G; Kraus J
    Mult Scler; 2011 Jan; 17(1):16-23. PubMed ID: 20937631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis.
    Johnson KP
    Neurologist; 2007 Jul; 13(4):182-7. PubMed ID: 17622909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.
    Calabresi PA; Giovannoni G; Confavreux C; Galetta SL; Havrdova E; Hutchinson M; Kappos L; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Lublin FD; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
    Neurology; 2007 Oct; 69(14):1391-403. PubMed ID: 17761550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of natalizumab on the innate and adaptive immune system in the central nervous system.
    Stüve O
    J Neurol Sci; 2008 Nov; 274(1-2):39-41. PubMed ID: 18474372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors.
    Saure C; Warnke C; Zohren F; Schroeder T; Bruns I; Cadeddu RP; Weigelt C; Fischer U; Kobbe G; Hartung HP; Adams O; Kieseier BC; Haas R
    Arch Neurol; 2011 Nov; 68(11):1428-31. PubMed ID: 22084125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab.
    Martin Mdel P; Cravens PD; Winger R; Kieseier BC; Cepok S; Eagar TN; Zamvil SS; Weber MS; Frohman EM; Kleinschmidt-Demasters BK; Montine TJ; Hemmer B; Marra CM; Stüve O
    Arch Neurol; 2009 Aug; 66(8):1016-20. PubMed ID: 19667224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Memory and naïve B-cell subsets in patients with multiple sclerosis.
    Niino M; Hirotani M; Miyazaki Y; Sasaki H
    Neurosci Lett; 2009 Oct; 464(1):74-8. PubMed ID: 19666086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis.
    Stüve O; Cepok S; Elias B; Saleh A; Hartung HP; Hemmer B; Kieseier BC
    Arch Neurol; 2005 Oct; 62(10):1620-3. PubMed ID: 16216948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab.
    del Pilar Martin M; Cravens PD; Winger R; Frohman EM; Racke MK; Eagar TN; Zamvil SS; Weber MS; Hemmer B; Karandikar NJ; Kleinschmidt-DeMasters BK; Stüve O
    Arch Neurol; 2008 Dec; 65(12):1596-603. PubMed ID: 18852339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells.
    Harrer A; Wipfler P; Einhaeupl M; Pilz G; Oppermann K; Hitzl W; Afazel S; Haschke-Becher E; Strasser P; Trinka E; Kraus J
    J Neuroimmunol; 2011 May; 234(1-2):148-54. PubMed ID: 21450349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells.
    Korporal M; Haas J; Balint B; Fritzsching B; Schwarz A; Moeller S; Fritz B; Suri-Payer E; Wildemann B
    Arch Neurol; 2008 Nov; 65(11):1434-9. PubMed ID: 19001161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increase of CD8+ T-effector memory cells in peripheral blood of patients with relapsing-remitting multiple sclerosis compared to healthy controls.
    Haegele KF; Stueckle CA; Malin JP; Sindern E
    J Neuroimmunol; 2007 Feb; 183(1-2):168-74. PubMed ID: 17084910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of bariatric surgery on peripheral blood lymphocyte subsets in women.
    Merhi ZO; Durkin HG; Feldman J; Macura J; Rodriguez C; Minkoff H
    Surg Obes Relat Dis; 2009; 5(2):165-71. PubMed ID: 18996763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Natalizumab in the treatment of multiple sclerosis].
    Horga A; Horga de la Parte JF
    Rev Neurol; 2007 Sep 1-15; 45(5):293-303. PubMed ID: 17876741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.